Afghanistan vs Mexico: Average cost of multi drug-resistant tuberculosis treatment
Afghanistan
1,000 constant 2022 US$
in 2024
Mexico
1,000 constant 2022 US$
in 2024
Afghanistan rank
48th
Mexico rank
48th
Average cost of multi drug-resistant tuberculosis treatment over time
- Afghanistan
- Mexico
How they compare
Afghanistan currently reports 1,000 constant 2022 US$ against 1,000 constant 2022 US$ in Mexico, a difference of 0 constant 2022 US$.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Afghanistan ahead.
Afghanistan ranks 48th and Mexico ranks 48th of 92 countries.
Afghanistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,450 constant 2022 US$ | 1,022 constant 2022 US$ | 428.5 constant 2022 US$ | Afghanistan |
| 2020s | 1,000 constant 2022 US$ | 986.2 constant 2022 US$ | 13.8 constant 2022 US$ | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Afghanistan or Mexico?
- Afghanistan, at 1,000 constant 2022 US$ against 1,000 constant 2022 US$ in Mexico as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Afghanistan and Mexico?
- 0 constant 2022 US$, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Mexico?
- 7 years are reported by both, from 2017 to 2024.
- How do Afghanistan and Mexico rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Afghanistan ranks 48th and Mexico ranks 48th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.